Physician profile
Zeema Daniel
NPI 1710576673
$3,111.41
in general payments reported to CMS, 2019-2025
15 companies · $877 in 2025
The $877 reported for 2025 was more than what 83% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $617 · 2023: $558 · 2024: $1,059 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,249 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,249.17 |
| Education | $245.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,225.72 | 2022-2025 | |
| Genzyme Corporation | $411.80 | 2022-2023 | |
| Amgen INC. | $322.65 | 2023-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $309.89 | 2024-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $213.66 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $154.67 | 2025 | |
| Pfizer INC. | $124.36 | 2022-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $82.38 | 2023 | Valchlor |
| Galderma Laboratories, L.P. | $61.23 | 2023 | Twyneo, Aklief, Oracea |
| Arcutis Biotherapeutics, INC. | $49.48 | 2025 | Zoryve |
| Ucb, INC. | $44.39 | 2025 | Bimzelx |
| Leo Pharma INC. | $37.61 | 2023-2024 | Adbry |
| Lilly USA, LLC | $29.87 | 2023 | Taltz |
| Organon LLC | $27.96 | 2025 | |
| Dermavant Sciences, INC. | $15.74 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeema Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.